Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Acq. announced
Quarterly results
Appointed director
CC transcript
PLUS THERAPEUTICS, INC. (CYTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Investor Contact"
02/23/2023 8-K Quarterly results
Docs: "Peter Vozzo ICR Westwicke 377-4767 [email protected] Terri Clevenger ICR Westwicke 856-4326 [email protected]"
07/21/2022 8-K Quarterly results
04/21/2022 8-K Quarterly results
Docs: "Plus Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights First patient dosed in ReSPECT-LM Phase 1/2a dose escalation trial of 186 RNL for leptomeningeal metastases"
02/24/2022 8-K Quarterly results
10/21/2021 8-K Quarterly results
Docs: "Plus Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights Management to host conference call today at 5:00 p.m. ET"
07/22/2021 8-K Quarterly results
Docs: "Plus Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights Management to host conference call today at 5:00 pm ET"
04/22/2021 8-K Quarterly results
02/22/2021 8-K Quarterly results
10/22/2020 8-K Quarterly results
Docs: "Plus Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights – Received FDA Orphan Drug and Fast Track designations for novel glioblastoma radiotherapy –"
05/14/2019 8-K Quarterly results
Docs: "Cytori Reports Q1 2019 Business and Financial Results"
04/01/2019 8-K Quarterly results
Docs: "Cytori Reports Fourth Quarter and Full Year 2018 Business and Financial Results Strategic focus on building a leading oncology company / Lorem Vascular cell therapy transaction yields $4MM Letter of intent for ATI-0918 filed with EMEA"
03/08/2018 8-K Quarterly results
Docs: "Cytori Reports Fourth Quarter and Full Year 2017 Business and Financial Results"
11/09/2017 8-K Quarterly results
Docs: "Cytori Reports Third Quarter 2017 Business and Financial Results"
08/10/2017 8-K Quarterly results
Docs: "Cytori Reports Second Quarter 2017 Business and Financial Results"
05/11/2017 8-K Quarterly results
Docs: "Cytori Reports First Quarter 2017 Business and Financial Results"
03/23/2017 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
08/04/2016 8-K Quarterly results
Docs: "Cytori Reports Second Quarter 2016 Business and Financial Results",
"Cytori Reports Second Quarter 2016 Business and Financial Results"
05/10/2016 8-K Quarterly results
Docs: "Cytori Reports First Quarter 2016 Business and Financial Results"
11/05/2015 8-K Quarterly results
Docs: "Cytori Reports Third Quarter 2015 Business and Financial Results"
08/06/2015 8-K Quarterly results
Docs: "Cytori Reports Second Quarter 2015 Business and Financial Results"
05/11/2015 8-K Quarterly results
Docs: "Cytori Reports First Quarter 2015 Business and Financial Results"
11/06/2014 8-K Quarterly results
Docs: "Cytori Reports Third Quarter 2014 Business and Financial Results"
08/11/2014 8-K Quarterly results
Docs: "Cytori Reports Second Quarter 2014 Business and Financial Results"
05/12/2014 8-K Quarterly results
Docs: "Cytori Reports First Quarter 2014 Business and Financial Results"
03/11/2014 8-K Quarterly results
Docs: "Cytori Reports Fourth Quarter and Full Year 2013 Business and Financial Results SAN DIEGO, March 11, 2014—Cytori Therapeutics reports its fourth quarter and year end 2013 business and financial results and provides an outlook for 2014. Cytori achieved total revenues for the year and fourth quarter ended December 31, 2013 of $12.2 million and $3.5 million, respectively, compared to $14.5 million and $7.3 million, respectively, for the same periods in 2012. Total product and contract revenue for 2013 increased 14% to $10.4 million, compared with $9.1 million in 2012, despite a reduction in product revenues of $1.6 million. Product revenues do not include $3.6 million in shipments to customers in 2013, which are expected to be recognized as revenue in 2014. Non recurring and non cash developm..."
11/07/2013 8-K Form 8-K - Current report
08/08/2013 8-K Form 8-K - Current report
05/09/2013 8-K Quarterly results
Docs: "Cytori Reports First Quarter 2013 Business and Financial Results"
03/07/2013 8-K Quarterly results
Docs: "Cytori Reports 2012 Business and Financial Results; Provides Outlook for 2013 - U.S. ATHENA trial on track for mid-2013 completion of enrollment with 1st data in 1H 2014 - - BARDA: Contract activities underway - - Achieved $9.1 million in product and contract revenue for 2012 - - Recent approvals in Japan and EU to drive continued revenue growth in 2013 and beyond - SAN DIEGO—Cytori Therapeutics reports its 2012 business and financial results and provides an outlook for 2013. The Company achieved record total revenues for the year and fourth quarter ended December 31, 2012 of $14.5 million and $7.3 million, respectively, compared to $10.0 million and $2.8 million, respectively, for the same periods in 2011. Milestone Highlights Cytori’s 2012 and year-to-date milestones include the followin..."
11/08/2012 8-K Form 8-K - Current report
08/08/2012 8-K Form 8-K - Current report
05/09/2012 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy